OptimizeRx Corporation Forecast, price target & analysts
OptimizeRx Corporation Target price 2025 - Analyst rating & recommendation
OptimizeRx Corporation Classifications & Recommendation:
OptimizeRx Corporation Price Target
| Target Price | $9.64 |
| Price | $5.14 |
| Potential |
87.60%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target OptimizeRx Corporation 2026 .
The average OptimizeRx Corporation target price is $9.64.
This is
87.60%
register free of charge
$16.00
211.28%
register free of charge
$5.50
7.00%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend OptimizeRx Corporation to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the OptimizeRx Corporation stock has an average upside potential 2026 of
87.60%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 71.52 | 90.45 |
| 14.52% | 26.47% | |
| EBITDA Margin | -15.13% | 10.30% |
| 8.01% | 168.08% | |
| Net Margin | -26.40% | -21.10% |
| 40.53% | 20.07% |
7 Analysts have issued a sales forecast OptimizeRx Corporation 2024 . The average OptimizeRx Corporation sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an OptimizeRx Corporation EBITDA forecast 2024. The average OptimizeRx Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 OptimizeRx Corporation Analysts have issued a net profit forecast 2024. The average OptimizeRx Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.03 | -1.04 |
| 60.94% | 0.97% | |
| P/E | negative | |
| EV/Sales | 1.26 |
4 Analysts have issued a OptimizeRx Corporation forecast for earnings per share. The average OptimizeRx Corporation <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the OptimizeRx Corporation stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
OptimizeRx Corporation...
Current OptimizeRx Corporation Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JMP Securities | Locked ➜ Locked | Locked | Feb 06 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Jan 08 2025 |
| B. Riley Securities | Locked ➜ Locked | Locked | Dec 24 2024 |
| Lake Street | Locked ➜ Locked | Locked | Dec 24 2024 |
| Stephens & Co. | Locked ➜ Locked | Locked | Dec 20 2024 |
| Barclays | Locked ➜ Locked | Locked | Nov 14 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
JMP Securities: Locked ➜ Locked
|
Feb 06 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
B. Riley Securities: Locked ➜ Locked
|
Dec 24 2024 |
|
Locked
Lake Street: Locked ➜ Locked
|
Dec 24 2024 |
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
Barclays: Locked ➜ Locked
|
Nov 14 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
